Melanotan I and Melanotan II: Melanocortin Receptor Research

Background: Alpha-MSH and the Melanocortin System

Alpha-melanocyte-stimulating hormone (alpha-MSH) is an endogenous peptide derived from the pro-opiomelanocortin (POMC) precursor. It acts on a family of five G-protein-coupled receptors designated MC1R through MC5R, collectively termed the melanocortin receptors. Alpha-MSH has broad biological activity; the most studied effects relate to skin pigmentation (MC1R), energy homeostasis (MC3R, MC4R), and sexual function (MC4R).

The native alpha-MSH peptide has limited utility as a research tool because of its short plasma half-life (approximately 30 minutes) and non-selective receptor binding profile across MC1R-MC4R. This motivated the development of synthetic analogues with modified stability and receptor selectivity profiles.

Melanotan I

Chemical Name: [Nle4, D-Phe7]-alpha-MSH

CAS Number: 75921-69-6

Molecular Weight: 1646.9 Da

Peptide Length: 13 amino acids

Melanotan I (MT-I, afamelanotide) is a linear synthetic analogue of alpha-MSH. Two substitutions differentiate it from the native peptide: norleucine (Nle) replaces methionine at position 4, and D-phenylalanine replaces L-phenylalanine at position 7. These substitutions dramatically increase potency and plasma half-life relative to native alpha-MSH (Hruby et al., 1987).

Receptor Selectivity

A defining characteristic of MT-I is its relatively selective binding to MC1R compared to MT-II. Binding affinity studies in human melanocyte cell lines show that MT-I has high affinity at MC1R, with progressively weaker binding at MC3R and MC4R. This selectivity profile makes MT-I a useful research tool for studies specifically targeting MC1R-mediated signalling pathways.

Melanogenesis Research

MC1R is expressed predominantly in melanocytes and is the primary receptor mediating the melanogenic response. MT-I activates MC1R and stimulates the cyclic AMP/PKA pathway, leading to upregulation of tyrosinase and MITF (microphthalmia-associated transcription factor), which are rate-limiting in the melanin biosynthesis pathway.

Preclinical research in cultured melanocytes and rodent models has consistently documented increased melanin production following MT-I administration. A key translational application has been its investigation in erythropoietic protoporphyria (EPP), a photosensitivity disorder in which MT-I-induced melanisation may provide photoprotection. Phase 3 clinical trials in EPP patients demonstrated significant reductions in phototoxic reactions versus placebo, leading to regulatory approval in Europe (Langendonk et al., 2015).

Photoprotection Research

Beyond EPP, research has examined whether MT-I-induced pigmentation offers protection against UV-induced DNA damage in normal skin. In vitro studies using human keratinocytes have examined MT-I effects on nucleotide excision repair pathway activation and UV-induced cyclobutane pyrimidine dimer formation. Some studies report reduced DNA damage markers with MT-I pre-treatment, though the mechanistic basis and clinical relevance remain under investigation.

Melanotan II

Chemical Name: Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-NH2

CAS Number: 121062-08-6

Molecular Weight: 1024.2 Da

Peptide Length: 7 amino acids (cyclic)

Melanotan II (MT-II) is a cyclic heptapeptide containing the minimal pharmacophore sequence (His-Phe-Arg-Trp) required for melanocortin receptor activation. The cyclic structure, formed by a lactam bridge between Asp and Lys, and the D-Phe substitution confer high metabolic stability and receptor affinity. MT-II is considerably more potent than MT-I at melanocortin receptors overall, with significant activity at MC1R, MC3R, and MC4R.

Receptor Activity Profile

Unlike MT-I, MT-II shows substantial binding affinity at MC4R as well as MC1R. MC4R is expressed in the hypothalamus and central nervous system and is involved in energy homeostasis, appetite regulation, and sexual function. This broader receptor activity profile means MT-II research spans multiple physiological domains simultaneously.

MC4R-selective agonism has been studied extensively in the context of energy balance. Preclinical models of diet-induced obesity have demonstrated that MC4R activation reduces food intake and increases energy expenditure, effects attributed to hypothalamic MC4R signalling (Fan et al., 1997).

Sexual Function Research

One of the most studied pharmacological properties of MT-II is its activity at MC4R in circuits governing sexual arousal. Early studies in male rats demonstrated erection in a significant proportion of subjects following systemic MT-II administration (Dorr et al., 1996). Subsequent human pilot studies found similar effects in men with psychogenic erectile dysfunction, leading to clinical interest in melanocortin pathway modulation for sexual dysfunction (Wessells et al., 1998).

The MC4R appears to be the principal receptor mediating these effects. Studies using selective MC4R antagonists have blocked MT-II-induced erection in rodent models, while MC1R-selective compounds lack this activity.

Melanogenesis

MT-II also induces melanogenesis via MC1R, though its lack of receptor selectivity relative to MT-I makes it a less specific research tool for isolated MC1R studies. The primary pigmentation pathway (MC1R/cAMP/MITF/tyrosinase) is activated by both compounds.

Structural Comparison

Key References

1. Hruby VJ, Wilkes BC, Hadley ME, al-Obeidi F, Sawyer TK, Staples DJ, de Vaux AE, Dym O, Castrucci AM, Hintz MF. "Alpha-Melanotropin: The Minimal Active Sequence in the Frog Skin Bioassay." *Journal of Medicinal Chemistry.* 1987;30(11):2126-2130.

2. Langendonk JG, Balwit JM, Lecluse MM, Baas A, Eling WM, Bernstein IA, Bruze G, Frank J, Harms J, Held U, Hofmann C, Janssen G, Jansen M, Mackey A, Milne A, Müller K, Neef C, Nijsten T, Nyberg F, Ruzicka T, Sancar A, Scharfetter-Kochanek K, Stender S, Stratigos A, Szczech J, van Dongen JJ, Wolff H, Hintzen RQ, Geleijnse ML, Weil EJ, Elferink MG. "Afamelanotide for Erythropoietic Protoporphyria." *New England Journal of Medicine.* 2015;373(1):48-59.

3. Fan W, Boston BA, Kesterson RA, Hruby VJ, Cone RD. "Role of Melanocortinergic Neurons in Feeding and the Agouti Obesity Syndrome." *Nature.* 1997;385(6612):165-168.

4. Dorr RT, Lines R, Levine N, Brooks C, Xiang L, Hruby VJ, Hadley ME. "Evaluation of Melanotan-II, a Superpotent Cyclic Melanotropic Peptide in a Pilot Phase-I Clinical Study." *Life Sciences.* 1996;58(20):1777-1784.

5. Wessells H, Levine N, Hadley ME, Dorr R, Hruby V. "Melanocortin Receptor Agonists, Penile Erection, and Sexual Motivation: Human Studies with Melanotan II." *International Journal of Impotence Research.* 2000;12(Suppl 4):S74-79.

Disclaimer: All information is based on published preclinical and clinical research literature and is provided for educational purposes only. Melanotan I and Melanotan II are sold strictly for in-vitro laboratory and research purposes. Not medical advice.